Baker McKenzie advised international life sciences venture capital investor Forbion on a $ 54 million Series A equity financing of Gotham Therapeutics Corporation ("Gotham"), based in the USA and Germany. This is the first investment by the recently raised fund Forbion IV, which has a total volume of € 360 million focusing on biopharma investment opportunities in Europe, Great Britain and the USA.
Gotham is a biotechnology company that is developing a novel class of drugs targeting the epitranscriptomics machinery with RNA-modifying proteins. In addition to the founding investor Versant Ventures, S.R. One. Celgene and Alexandria Venture Investments were involved in this successful first financing round.
Baker McKenzie advised Forbion with a German-American team of lawyers led by Munich based corporate partner Berthold Hummel on all legal aspects of German and Delaware law in connection with equity financing and selected cross-border corporate law aspects.
"We were able to help Forbion in this exciting Series A financing of Gotham Therapeutics with our remarkable expertise on cross-border venture capital investments in US target companies", comments Baker McKenzie Corporate Partner Berthold Hummel.
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, the company aims to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases.
Forbion is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. Forbion currently manages over €1 bn across ten closed-end funds and has a team of thirteen investment professionals across two offices.
Baker McKenzie's Corporate / M&A team regularly advises financial investors on domestic and international transactions. Most recently, Baker McKenzie advised DBAG Fund VII on its investment in Kraft & Bauer Holding, Syngroh Capital on its investment in KMLS, financial investors First State Investments and Hermes Investment Management on the acquisition of the shipping company Scandlines from 3i Group plc, Forbion Capital Fund III on the seed and Series A financing of CatalYm and Daimler on a number of venture investments.
Legal advisor to Forbion Capital Fund IV
Lead: Berthold A. Hummel (Corporate/M&A, Partner, Munich),
Team: Corporate/M&A Munich: Julia Braun (Counsel), Dr. Katja Heuterkes (Counsel), Matthias Schmitz (Law Clerk)
Corporate/M&A Washington: Marc R. Paul (Partner), Nathaniel Douglas (Senior Associate), Geoffrey Hainbach (Associate)